U.S. stock market is gliding lower Friday morning in early trading after pathetic earnings outcomes and outlooks from some big-name companies. United Parcel Service (UPS) pre-declared Q4 earnings well under analysts’ prospects, putting on to investors’ worries for the earnings season pursuant to mixed results from Dow components McDonalds (MCD) and General Electric (GE).
Asian traders took their turn countering earnestly to Thursday’s European Central Bank declaration. But notwithstanding early losses, Wall Street is still on the edge to snap a three-week losing strip.
U.S. stocks cut down Friday, giving up some ground after four sessions of gains that lifted the S&P 500 to its peak close of the year.
The Dow Jones Industrial Average lost 57 points, or 0.3%, to 17757. The S&P 500 fell 6 points, or 0.3%, to 2057 and the Nasdaq Composite slipped a fraction to 4750.
Biotechnology Index Today:
Health Care SPDR (XLV), Vanguard Health Care ETF (VHT) and iShares Dow Jones US Healthcare (IYH) were flat. Biotechnology fund iShares NASDAQ Biotechnology Index (IBB) was down 0.03%.
The post-J.P. Morgan loom set in this week. Biotech news deliberated, largely aside from President Obama’s Precision Medicine Initiative and a pageant of follow-on financings. Indeed, as 2015 kicks off, optimism remains unbridled in the sector: the NASDAQ Biotechnology Index (NASDAQ: IBB) is hitting record highs.
Latest News and Performances of few well-known Biotechnology shares, during their current trading session, are described underneath:
Array BioPharma, Inc. (NASDAQ:ARRY), inclined massively 38.02%, and is now at $6.97, holding market capitalization of $919.80M, as the company has reached a definitive contract today, with Novartis Pharma AG to attain worldwide rights to encorafenib (LGX818), a BRAF inhibitor presently in Phase 3 development. This contract is conditional on the closing of transactions affirmed by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are anticipated to close in the first half of 2015, and the contract remains subject to the receipt of authoritarian approvals.
Array BioPharma, Inc. (ARRY), is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Gilead Sciences Inc. (NASDAQ:GILD), declined 0.48%, after John F. Milligan, PhD, Gilead’s President and Chief Operating Officer, provided an overview of the company at the conference on Tuesday, January 13.
Gilead Sciences Inc. (GILD), is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
Vertex Pharmaceuticals Incorporated, (NASDAQ:VRTX), declined 1.45%, after the company on January 11, 2015, sketched 2015 business priorities to bear the development, approval and launch of new medicines that treat the underlying cause of cystic fibrosis (CF). The corporation also provided 2015 guidance for KALYDECO® (ivacaftor) net revenues and for non-GAAP operating expenses. These updates were made in juxtaposition with the 33rd Annual J.P. Morgan Healthcare Conference that was held in San Francisco on Monday, January 12.
Vertex Pharmaceuticals Incorporated, (NASDAQVRTX), is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives.
Celgene Corporation (NASDAQ:CELG), dwindled 0.91%, as the company’s subsidiary Celgene International Sàrl, declared that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has taken on positive attitude for ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in mishmash with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Celgene Corporation (NASDAQ:CELG), headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
MannKind Corp. (NASDAQ:MNKD), surged 1.97%, after the company declared that Alfred Mann, the company’s founder, stepped down from his role as Chief Executive Officer effective January 9, 2015 and will shift to Executive Chairman. Mr. Mann proposes to remain engaged with the company in business matters, together with those relating to development and financing of MannKind’s future therapies. On January 9, 2015, MannKind’s Board of Directors selected Hakan Edstrom, present President of MannKind, as the new Chief Executive Officer of the company. Mr. Edstrom will keep hold of his title as President.
MannKind Corp. (NASDAQ:MNKD), focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.
Radius Health, Inc. (NASDAQ:RDUS), climbed 3.92%, and is now at $38.98, holding market capitalization of $1.28B, after the company declared that it has priced its public offering of 4,000,000 shares of its ordinary stock at a public offering price of $36.75 per share. Additionally, the Company has granted the underwriters an alternative to purchase up to an additional 600,000 shares of its ordinary stock, exercisable for 30 days.
Radius Health, Inc. (NASDAQ:RDUS), a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States.
XOMA Corporation (NASDAQ:XOMA), plunged 2.71% , and is now at $3.41. The company has the market capitalization of $365.68M. It is trading in a range of $3.35 - $3.52, whereas it kept 52-week high of $9.57.
XOMA Corporation (NASDAQ:XOMA), discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific.
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), skyrocketed 27.02%, and is currently at $15.23, holding market capitalization of 274.54M, as the firm declared the pricing of its follow-on public offering of 3,000,000 shares of its ordinary stock at $11.90 per share. All shares of ordinary stock to be sold in the offering are being offered by Vitae. Vitae has also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of ordinary stock.
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer’s disease.
